Apoptosis-based therapies

Nature Reviews Drug Discovery

Volumn 1, Issue 2, 2002, Pages 111-121

  Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ADVEXIN; APOPTOSIS INHIBITOR; CGP3466B; CILENGITIDE; E1A; E1A PROTEIN; MEMANTINE; MONOCLONAL ANTIBODY LM 609; OBLIMERSEN; ONYX 015; PRALNACASAN; SULINDAC SULFONE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VORINOSTAT; APAF1 PROTEIN, HUMAN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE; INHIBITOR OF APOPTOSIS PROTEIN; INSECT PROTEIN; PROTEIN; TRANSCRIPTION FACTOR;

ALZHEIMER DISEASE; ANGIOGENESIS; APOPTOSIS; ARTHRITIS; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; DRUG TOLERANCE; HEAD AND NECK CANCER; HEPATITIS; HUMAN; LEUKEMIA; LIVER INJURY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIINFARCT DEMENTIA; MYELOMA; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; REVIEW; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENE THERAPY; GENETICS; NEOPLASM; PHYSIOLOGY; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CASPASES; GENE THERAPY; GENES, BCL-2; GENES, P53; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INSECT PROTEINS; NEOPLASMS; PROTEINS; TRANSCRIPTION FACTORS;

EID: 0036463649     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd726     Document Type: Review

References (121)

1. Engelberg-Kulka, H. & Glaser, G. Addiction modules and programmed cell death and antideath in bacterial cultures. Annu. Rev. Microbiol. 53, 43-70 (1999).
2. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462 (1995).
3. Reed, J. C. Mechanisms of apoptosis. Am. J. Pathol. 157, 1415-1430 (2000).
4. Thornberry, N. & Lazebnik, Y. Caspases: enemies within. Science 281, 1312-1316 (1998).
5. Li, P. et al. Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell 80, 401-411 (1995).
6. Bergeron, L. et al. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev. 12, 1304-1314 (1998).
7. Wang, S. et al. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell 92, 501-509 (1998).
8. Ona, V. O. et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399, 263-267 (1999). This paper showed that caspase inhibition could slow the progression of a chronic neurodegenerative disease in an animal model, and therefore strengthened the cause-and-effect linkage between caspases and severity or kinetics of neurodegeneration.
9. Endres, M. et al. Attentuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family J. Cereb. Blood Flow Metab. 18, 238-247 (1998).
10. Holly, T. A. et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J. Mol. Cell. Cardiology 31, 1709-1715 (1999).
11. Wiessner, C., Sauer, D., Alaimo, D. & Allegrini, P. R. Protective effect of a caspase inhibitor in models for cerebral ischemia in vitro and in vivo. Cell. Mol. Biol. 46, 53-62 (2000).
12. Rabuffetti, M. et al. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J. Neurosci. 20, 4398-4404 (2000).
13. Li, M. et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288, 335-339 (2000).
14. Lee, D. et al. Potent and selective nonpeptide inhibitors of caspases 3 and 7. J. Med. Chem. 44, 2015-2026 (2001).
15. Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810-816 (2000).
16. Reed, J. C. & Tomaselli, K. Drug discovery opportunities from apoptosis research. Curr. Opin. Biotechnol. 11, 586-592 (2000).
17. Green, D. R. & Reed, J. C. Mitochondria and apoptosis. Science 281, 1309-1312 (1998).
18. Li, P. et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479-489 (1997). The first paper to describe the 'apoptosome' -a holoenzyme complex that maintains caspase-9 in an active conformation - and define its minimal components: APAF1, caspase-9 and cytochrome c.
19. Qin, H. et al. Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1. Nature 399, 549-557 (1999).
20. Zou, H., Li, Y., Liu, X. & Wang, X. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274, 11549-11556 (1999).
21. Saleh, A., Srinivasula, S., Acharya, S., Fishel, R. & Alnemri, E. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J. Biol. Chem. 274, 17941-17945 (1999).
22. Salvesen, G. S. & Dixit, V. M. Caspase activation: the induced-proximity model. Proc. Natl Acad. Sci. USA 96, 10964-10967 (1999).
23. Hakem, R. et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94, 339-352 (1998).
24. Chou, J. Matsuo, H., Duan, H. & Wagner, G. Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment. Cell 94, 171-180 (1998).
25. Ruland, J. et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure. Cell 104, 33-42 (2001).
26. Yeh, W. et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279, 1954-1958 (1998).
27. Zhang, J., Cado, C., Chen, A., Kabra, N. & Winoto, A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort 1. Nature 332, 296-299 (1998).
28. Kuang, A. A., Diehl, G. E., Zhang, J. & Winoto, A. FADD is required for DR4- and DR5-mediated apoptosis: lack of TRAIL-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J. Biol. Chem. 275, 25065-25068 (2000).
29. Deveraux, Q. & Reed. J. IAP family proteins: suppressors of apoptosis. Genes Dev. 13, 239-252 (1999).
30. La Casse, E. C., Baird, S., Korneluk, R. G. & MacKenzie, A. E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17, 3247-3259 (1998).
31. Fesik, S. W. Insights into programmed cell death through structural biology. Cell 103, 273-282 (2000).
32. Yang, Y., Fang, S., Jensen, J., Weissman, A. & Ashwell, J. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288, 874-877 (2000).
33. Ambrosini, G., Adida, C. & Altieri, D. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917-921 (1997). The first report of the IAP-family member survivin, and the first study to show that some IAPs are over-produced in cancers.
34. Vucic, D., Stennicke, H. R., Pisabarro, M. T., Salvesen, G. S. & Dixit, V. M. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 10, 1359-1366 (2000).
35. Chen, J. et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2, 235-241 (2000).
36. Holcik, M. et al. The hippocampal neurons of neuronal apoptosis inhibitory protein 1 (NAIP1)-deleted mice display increased vulnerability to kainic acid-induced injury. Proc. Natl Acad. Sci. USA 97, 2286-2290 (2000).
37. Xu, D. G. et al. Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nature Med. 3, 997-1004 (1997). An early study that shows that gene-transfer-mediated elevations in the expression of IAP-family proteins can provide neuroprotection in vivo. This paper applied NAIP (the first human IAP to be discovered) in an animal model of cerebral ischaemia.
38. Xu, D. et al. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. J. Neurosci. 19, 5026-5033 (1999).
39. Adams, J. & Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science 281, 1322-1326 (1998).
40. Gross, A., McDonnell, J. & Korsmeyer, S. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13, 1899-1911 (1999).
41. Huang, D. C. & Strasser, A. BH3-only proteins - essential initiators of apoptotic cell death. Cell 103, 839-842 (2000).
42. Dubois-Dauphin, M., Frankowski, H., Tsujimoto, Y., Huarte, J. & Martinou, J.-C. Neonatal motoneurons overexpressing the Bcl-2 protooncogene in transgenic mice are protected from axotomy-induced cell death. Proc. Natl Acad. Sci. USA 91, 3309-3313 (1994).
43. Cenni, M. C. et al. Long-term survival of retinal ganglion cells following optic nerve section in adult Bcl-2 transgenic mice. Eur. J. Neurosci. 8, 1735-1745 (1996).
44. Linnik, M. D., Zahos, P., Geschwind, M. D. & Federoff, H. J. Expression of Bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke 26, 1670-1674 (1995).
45. Kostic, V., Jackson-Lewis, V., de Bilbao, F., Dubois-Dauphin, M. & Przedborski, S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277, 559-562 (1997). This report provided direct evidence that an apoptosis-blocking protein (BCL2) could prolong survival in an animal model of a chronic neurodegenerative disease, and therefore strengthened the cause-and-effect linkage between the apoptotic machinery and severity or kinetics of neurodegeneration.
46. Haldar, S., Jena, N. & Croce, C. M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl Acad. Sci. USA 92, 4507-4511 (1995).
47. Cheng, E. et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278, 1966-1968 (1997).
48. Sagot, S. et al. Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse. Eur. J. Neurosci. 7, 1313-1322 (1995).
49. L bound to an inhibitory BH3 peptide laid the foundation for subsequent attempts to screen for, or derive by rational means, small-molecule antagonists of BCL2-family proteins.
50. Wang, J.-L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 197, 7124-7129 (2000). This paper provided the first evidence that small-molecule inhibitors of BCL2 could be produced.
51. L. Nature Cell Biol. 3, 173-182 (2001).
52. Tzung, S. et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nature Cell Biol. 3, 183-192 (2001).
53. Kroemer, G. & Reed, J. C. Mitochondrial control of cell death. Nature Med. 6, 513-519 (2000).
54. Bernardi, P. et al. The mitochondrial permeability transition. Biofactors 8, 273-281 (1998).
55. Sagot, Y. et al. An orally active anti-apoptotic molecule (CGP3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease. Br. J. Pharmacol. 131, 721-728 (2000).
56. Kragten, E. et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the anti-apoptotic compounds CGP3466 and R-(-)-deprenyl. J. Biol. Chem. 273, 5821-5826 (1998).
57. Tatton, W. G. & Chalmers-Redman, R. M. E. Modulation of gene expression rather than monoamine oxidase inhibition (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47, S171-S183 (1996).
58. Yang, D. D. et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389, 865-870 (1997). This work used a Jnk3 knockout mouse to validate this protein kinase as a potential drug discovery target for neuronal cell death.
59. Ichijo, H. et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275, 90-94 (1997).
60. Geleziunas, R., Xu, W., Takeda, K., Ishijo, H. & Greene, W. C. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 410, 834-638 (2001).
61. Kissil, J. L. & Kimchi, A. Death-associated proteins: from gene identification to the analysis of their apoptotic and tumour suppressive functions. Mol. Med. Today 4, 268-274 (1998).
62. Datta, S., Brunet, A. & Greenberg, M. Cellular survival: a play in three Akts. Genes Dev. 13, 2905-2927 (1999).
63. Wang, H.-G. et al. Calcineurin promotes apoptosis by dephosphorylating BAD. Science 284, 339-343 (1998).
64. Kaul, M., Garden, G. A. & Lipton, S. A. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410, 988-994 (2001).
65. Di Cristafano, A. & Pandolfi, P. P. The multiple roles of PTEN in tumor suppression. Cell 100, 387-390 (2000).
66. Kim, A. H., Khursigara, G., Sun, X., Franke, T. F. & Chao, M. V. AKT1 phosphorylates and negatively regulates ASK1. Mol. Cell. Biol. 21, 893-901 (2001).
67. Pekarsky Y. et al. Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proc. Natl Acad. Sci. USA 98, 3690-3694 (2001).
68. Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292, 1728-1731 (2001).
69. Lietzke, S. E. et al. Structural basis of 3-phosphoinositide recognition by pleckstrin homology domains. Mol. Cell 6, 385-394 (2000).
70. Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98, 10314-10319 (2001).
71. Silverman, N. & Maniatis, T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev. 15, 2321-2342 (2001).
72. Lee, H. H., Dadgostar, H., Cheng, Q., Shu, J. & Cheng, G. NF-κB-mediated up-regulation of BCL-x and BFL-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc. Natl Acad. Sci. USA 96, 9136-9141 (1999).
73. Chu, Z. L. et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc. Natl Acad. Sci. USA 94, 10057-10062 (1997).
74. Stehlik, C. et al. Nuclear factor (NF)-κB-regulated X-chromosome-linked IAP gene expression protects endothelial cells from tumor necrosis factor-α-induced apoptosis. J. Exp. Med. 188, 211-216 (1998). This investigation showed a direct link between NF-κB and the expression of IAP-family genes, indicating that the induction of IAP expression represents an important mechanism by which NF-κB prevents TNFα-induced apoptosis in normal cells.
75. Rossi, A. et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403, 103-108 (2000). Shows that certain types of prostaglandins (cyclopentone-type) directly inhibit IKKs. The study provided insights into the anti-inflammatory properties of some prostaglandins, and proposed routes to the discovery of small-molecule antagonists of IKKs.
76. Holmes-McNary, M. & Baldwin, A. S. J. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase. Cancer Res. 60, 3477-3483 (2000).
77. Sporn, M. B., Suh, N. & Mangelsdorf, D. J. Prospects for prevention and treatment of cancer with SPARMs (selective PPARγ modulators). Trends Mol. Med. 7, 395-400 (2001).
78. Adams, J., Palombella, V. J. & Elliott, P. J. Proteasome inhibition: a new strategy in cancer treatment. Invest. New Drugs 18, 109-121 (2000).
79. Thompson, W. J., et al. Exisulind induction of apoptosis involves guanosine 3,5-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res. 60, 3338-3342 (2000).
80. Goluboff, E. T. et al. Safety and efficacy of Exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J. Urol. 166, 882-886 (2001).
81. Pratt, M. A. C. et al. Bcl-2 is required to prevent estrogen withdrawal-induced human breast cancer tumour regression. FEBS Lett. 440, 403-408 (1998).
82. Andreeff, M. et al. Expression of Bcl-2 family genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 13, 1881-1892 (1999).
83. Blutt, S. E., McDonnell, T. J., Polek, T. C. & Weigel, N. L. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141, 10-17 (2000).
84. Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D. & DuBois, R. N. Modulation of apoptosis and Bcl-2 expression by progtaglandin E2 in human colon cancer cells. Cancer Res. 58, 362-366 (1998).
85. Tsujii, M. & DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83, 493-501 (1995).
86. Zhang, L., Yu, J., Park, B. H., Kinzler, K. W. & Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science 290, 989-992 (2000).
87. Sun, M. et al. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor-α (ERα) via interaction between ERα and PI3K. Cancer Res. 61, 5985-5991 (2001).
88. Kousteni, S. et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104, 719-730 (2001). A study that provided in vivo evidence that steroid-hormone receptors can have transcription-independent mechanisms linked to apoptosis regulation.
89. Li, H. et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 289, 1159-1164 (2000). Showed that steroid/retinoid-family transcription factors can function outside the nucleus to regulate apoptosis, indicating opportunities for the development of small-molecule drugs that modulate this non-nuclear, non-transcriptional activity.
90. Brenner, C. & Kroemer, G. Apoptosis. Mitochondria - the death signal integrators. Science 289, 1150-1151 (2000).
91. Richon, V. M., Zhou, X., Rifkind, R. A. & Marks, P. A. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol. Dis. 27, 260-264 (2001).
92. Grooteclaes, M. L. & Frisch, S. M. Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene 19, 3823-3828 (2000).
93. Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376 (1996). Revealed that a mutant adenovirus only replicates in p53-deficient cells, setting the stage for subsequent clinical trials that were intended to exploit this property for treating cancer patients with p53-deficient tumours.
94. Khuri, F. R. et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med. 6, 879-885 (2000).
95. Miyashita, T. & Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of human BAX gene. Cell 80, 293-299 (1995). This report provided the first evidence that p53 directly binds to the promoter of a pro-apoptotic gene (BAX) and induces its transcription, thereby providing the first direct link between p53 and the apoptosis machinery. Subsequently, p53 was shown to directly transactivate several pro-apoptotic genes, including other members of the BCL2 family and some of the TNF-family of death receptors.
96. Oda, E. et al. NOXA, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053-1058 (2000).
97. Nakano, K. & Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683-694 (2001).
98. Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W. & Vogelstein, B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7, 673-682 (2001).
99. Owen-Schaub, L. B. et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. 15, 3032-3040 (1995).
100. Wu, G. S. et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet. 17, 141-143 (1997).
101. Roth, J. A., Swisher, S. G. & Meyn, R. E. p53 tumor suppressor gene therapy for cancer. Oncology 13, 148-154 (1999).
102. Foster, B., Coffey, H., Morin, M. & Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510 (1999).
103. Komarov, P. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733-1737 (1999).
104. Ashkenazi, A. & Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11, 255-260 (1999).
105. Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H. & Jurlander, J. The chimeric anti-CD20 antibody Rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 MAP-kinase dependent mechanism. Blood (in the press).
106. Byrd, J. C. et al. The mechanism of tumor cell clearance by Rituximab in vivo in patients with B-cell chronic lymphocytic leukemia involves apoptosis via a caspase-9 pathway. Blood (in the press).
107. 3. Clin. Cancer Res. 6, 3056-3061 (2000).
108. Digicaylioglu, M. & Lipton, S. A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades. Nature 412, 641-647 (2001). This paper showed a neuroprotective effect for erythropoietin, indicating possibilities of a new clinical application for this growth factor.
109. Ray J. & Gage, P. H. Construction of cells expressing neurotrophins. Methods Mol. Biol. 169, 115-133 (2001).
110. Paris, F. et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297 (2001).
111. +-ATPase. Proc. Natl Acad. Sci. USA 92, 5965-5968 (1995).
112. Sun, J. et al. A new family of 10 murine ovalbumin serpins includes two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9). J. Biol. Chem. 272, 15434-15441 (1997).
113. Nakagawa, T. et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 403, 98-103 (2000). Suggested a pathway that links stress in the endoplasmic reticulum (ER) to caspase activation.
114. Mancini, M. et al. Caspase-2 is localized at the Golgi complex and cleaves golgin-160 during apoptosis. J. Cell Biol. 149, 603-612 (2000).
115. Wang, Z.-G. et al. PML is essential for multiple apoptotic pathways. Nature Genet 20, 266-272 (1998).
116. Hess, J. L. & Korsmeyer, S. J. Life, death and nuclear spots. Nature Genet. 20, 220-222 (1998). Provided in vivo evidence that the nuclear protein PML modulates the apoptosis-sensitivity of cells.
117. Riedl, S. J. et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell 104, 791-800 (2001).
118. Du, C., Fang, M., Li, Y., Li, L. & Wang, X. SMAC, a mitochondrial protein that promotes cytochrome independent caspase activation by eliminating IAP inhibition. Cell 102, 33-42 (2000).
119. Verhagen, A. M. et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43-53 (2000). References 118 and 119 describe the discovery of a mitochondrial protein that is released into the cytosol during apoptosis, and which binds and inhibits IAP-family proteins. Subsequent structural studies of these endogenous IAP antagonists indicated a possible way of discovering small-molecule mimics.
120. Suzuki, Y. et al. A serine protease HTRA2/Omi, which is released from the mitochondria and interacts with XIAP, induces caspase-independent cell death. Mol. Cell 8, 613-621 (2001).
121. Srinivasula, S. M. et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410, 112-116 (2001)